XML 70 R17.htm IDEA: XBRL DOCUMENT
v3.20.1

Share Capital | 12 Months Ended
--- | ---
Dec. 31, 2019
Equity [Abstract] |
Share Capital | NOTE 9 - SHARE CAPITAL Share Capital Developments: On September 10, 2019, the Company reduced its authorized number of shares of capital stock from 221,000,000 to 61,000,000, including a reduction in the number of authorized shares of common stock of the Company from 220,000,000 to 60,000,000. As of December 31, 2019, the Company had 7,185,628 shares of common stock issued and outstanding. On December 27, 2016, the Company exchanged 655,962 shares (9,735,925 shares before the Reverse Split) or rights to acquire shares of its common stock, for 9,736 shares of a newly designated class of Series A Convertible Preferred Stock. On January 5, 2017, the Company entered into a definitive securities purchase agreement with an institutional investor (the “Purchaser”) for the purchase and sale of an aggregate of 47,163 shares (700,000 shares before the Reverse Split) of common stock in a registered direct offering for $74.00 per share ($5.00 per share before the Reverse Split) or gross proceeds of $3,500. The Company paid the placement agent a fee of $210 plus reimbursement of out-of-pocket expenses, as well as other offering-related expenses. On June 5, 2017, the Company entered into a Securities Purchase Agreement with certain institutional investors (the “Investors”) providing for the issuance and sale by the Company to the Investors of an aggregate of 252,652 shares (3,750,000 shares before the Reverse Split) of common stock, at a purchase price per share of $40.50 ($2.70 before the Reverse Split). The gross proceeds to the Company was $10,125 before deducting placement agent fees and offering expenses of $922. See Note 8 – “Commitments and Contingencies-Litigation” with respect to rescission rights awarded to two affiliated Investors and being sought by the other Investors. On January 14, 2019, the Company entered into a Securities Purchase Agreement with an accredited institutional investor providing for the issuance and sale by the Company to the purchaser of an aggregate of (i) 330,000 shares of the Company’s common stock, at a purchase price per share of $6.50 and (ii) 125,323 pre-funded warrants each to purchase one share of common stock, at a purchase price per Pre-Funded Warrant of $6.49. The gross proceeds to the Company were approximately $3,000 before deducting placement agent fees and other offering expenses of approximately $688. The closing of the offering took place on January 15, 2019. The pre-funded warrants were exercised in full in January 2019. As part of the offering the company issued to the underwriter 22,767 warrants for 3.5 years with an exercise price of $8.125 for total value of $165. On January 15, 2019, the Company entered into a Securities Purchase Agreement with certain accredited institutional investors providing for the issuance and sale by the Company to the purchasers of an aggregate of 590,000 shares of the Company’s common stock, at a purchase price per share of $10.00. The gross proceeds to the Company were approximately $5,900 before deducting placement agent fees and other offering expenses of approximately $720. The closing of the offering took place on January 17, 2019. As part of the offering the company issued to the underwriter 29,500 warrants for 3.5 years with exercise price of $12.50 for total value of $221. On January 23, 2019 the Company entered into a Securities Purchase Agreement with accredited institutional investors providing for the issuance and sale by the Company to the purchasers of an aggregate of 250,000 shares of the Company’s common stock, at a purchase price per share of $9.875. The investors also purchased warrants to purchase an aggregate of up to 250,000 shares of the Company’s common stock, at a purchase price per warrant of $0.125. The warrants were exercisable for 1 year and had an exercise price of $10.00 per share, for a total value of $2,019. The gross proceeds to the Company from the sale of the shares and warrants were approximately $2,500 before deducting placement agent fees and other offering expenses of approximately $370. The closing of the offering took place on January 25, 2019. As part of the offering the company issued to the underwriter 12,500 warrants for 1 year with an exercise price of $12.50 for total value of $99. On December 25, 2019 the Company entered into a Securities Purchase Agreement with accredited institutional investors providing for the issuance and sale by the Company to the purchasers of an aggregate of 912,858 shares of the Company’s common stock, at a purchase price per share of $10.50. The gross proceeds to the Company were approximately $9,585 before deducting placement agent fees and other offering expenses of approximately $1,090. The closing of the offering took place on December 27, 2019. As part of the offering the Company issued to the underwriter 45,643 warrants for 3.5 years with an exercise price of $13.125 for total value of $371. On December 27, 2019 the Company entered into a Securities Purchase Agreement with accredited institutional investors providing for the issuance and sale by the Company to the purchasers of an aggregate of 952,383 shares of the Company’s common stock, at a purchase price per share of $10.50. The gross proceeds to the Company were approximately $10,000 before deducting placement agent fees and other offering expenses of approximately $1,010. The closing of the offering took place on December 30, 2019. As part of the offering the Company issued to the underwriter 47,619 warrants for 3.5 years with an exercise price of $13.125 for total value of $366. On December 30, 2019 the Company entered into a Securities Purchase Agreement with accredited institutional investors providing for the issuance and sale by the Company to the purchasers of an aggregate of 900,901 shares of the Company’s common stock, at a purchase price per share of $11.10. The gross proceeds to the Company were approximately $10,000 before deducting placement agent fees and other offering expenses of approximately $1,010. The closing of the offering took place on December 31, 2019. As part of the offering the Company issued to the underwriter 45,045 warrants for 3.5 years with an exercise price of $13.875 for total value of $343. Employee Stock Option Grant In September 2014, Microbot Israel’s board of directors approved a grant of 26,906 stock options (403,592 stock options before the Reverse Split) (77,846 stock options as retroactively adjusted to reflect the Merger) to its CEO, through MEDX Venture Group LLC. Each option was exercisable into an ordinary share, at an exercise price of $12.00 ($0.80 before the Reverse Split) ($4.20 as retroactively adjusted to reflect the Merger). The stock options were fully vested at the date of grant. On May 2, 2016, Microbot Israel’s board of directors approved a grant of 33,333 stock options (500,000 stock options before the Reverse Split) (96,482 as retroactively adjusted to reflect the Merger) to certain of its employees and directors. Each stock option was exercisable into an ordinary share, NIS 0.001 par value, of Microbot Israel, at an exercise price equal to the ordinary share’s par value. The stock options were fully vested at the date of grant. As the exercise price of the stock options is nominal, Microbot Israel estimated the fair value of the options as equal to the Company’s share price of $20.25 ($1.35 before the Reverse Split) ($7.05 as retroactively adjusted to reflect the Merger) at the date of grant. On September 12, 2017, the Company adopted the 2017 Equity Incentive Plan (the “Plan”), which Plan authorizes, among other things, the grant of options to purchase shares of common stock to directors, officers and employees of the Company and to other individuals. On September 14, 2017, the board of directors approved a grant of stock options to purchase an aggregate of up to 120,848 shares (1,812,712 shares before the Reverse Split) of common stock to Mr. Harel Gadot, the Company’s Chairman of the Board, President and CEO, at an exercise price per share of $15.75 ($1.05 before the Reverse Split). The stock options vest over a period of 3-5 years as outlined in the option agreements. As a result, the Company recognized compensation expenses as of December 31, 2019 and 2018 in total amount of $482 and $581, respectively, included in general and administrative expenses. On September 14, 2017, the board of directors approved a grant of stock options to purchase an aggregate of up to 72,508 shares (1,087,627 shares before the Reverse Split) of common stock to Mr. Hezi Himelfarb, the Company’s General Manager, COO and a member of the Board, at an exercise price per share of $19.35 ($1.29 before the Reverse Split). The grant was subject to the Israeli Tax Authority’s approval of the plan which occurred on October 14, 2017. In accordance with the option agreement, the options vest for period of 3 years starting from the grand date. As a result, the Company recognized compensation expenses as of December 31, 2019 and 2018 in the total amount of $322 and $431, respectively, included in research and development. On December 6, 2017, the board of directors approved a grant of 12,698 stock options (190,475 stock options before the Reverse Split) to purchase an aggregate of up to 12,698 shares of common stock to certain of its directors, at an exercise price per share of $15.75 ($1.05 before the Reverse Split). The stock options vest over a period of 3 years as outlined in the option agreements. As a result, the Company recognized compensation expenses as of December 31, 2019 and 2018 in the total amount of $54 and $67, respectively, included in general and administrative expenses. On December 28, 2017, the board of directors approved a grant of 66,036 stock options (990,543 stock options before the Reverse Split) to purchase an aggregate of up to 66,036 shares of common stock to certain of its employees, at an exercise price per share of $15.3 ($1.02 before the Reverse Split). The stock options vest over a period of 3 years as outlined in the option agreements. As a result, the Company recognized compensation expenses as of December 31, 2019 and 2018 in the total amount of $149 and $307, respectively, included in research and development expenses. On November 2017, certain employees and consultant exercised 31,453 options (471,794 options before the Reverse Split) to 31,453 ordinary shares at exercise price of 0.001 NIS. In February 2018, an employee exercised options to purchase 2,487 shares (37,300 shares before the Reverse Split) of common stock at an exercise price of $0.001 per share. On August 13, 2018, the board of directors approved a grant of stock options to purchase an aggregate of up to 10,000 shares (150,000 shares before the Reverse Split) of common stock to a non-executive officer, at an exercise price per share of $9 ($0.6 before the Reverse Split). The grant was subject to the Israeli Tax Authority’s approval of the plan which occurred on October 14, 2017. In accordance with the option agreement, the options vest for period of 3 years starting from the grand date. As a result, the Company recognized compensation expenses as of December 31, 2019 and 2018 in the total amount of $31 and $11, respectively, included in research and development expenses. On January 21, 2019, the board of directors approved a grant of 11,630 stock options to purchase an aggregate of up to 11,630 shares of common stock to certain of its directors, at an exercise price per share of $8.60. The stock options vest over a period of 3 years as outlined in the option agreements As a result, the Company recognized compensation expenses as of December 31, 2019 and 2018 in the total amount of $43 and $0, respectively, included in general and administrative expenses. On August 12, 2019, the board of directors approved a grant of 17,503 stock options to purchase an aggregate of up to 17,503 shares of common stock to certain of its employees, at an exercise price per share of $5.95. The stock options vest over a period of 3 years as outlined in the option agreements. As a result, the Company recognized compensation expenses as of December 31, 2019 and 2018 in the total amount of $13 and $0, respectively, included in general and administrative expenses. On October 23, 2019, the board of directors approved a grant of 19,760 stock options to purchase an aggregate of up to 19,760 shares of common stock to certain of its directors, at an exercise price per share of $5.06. The stock options vest over a period of 3 years as outlined in the option agreements. As a result, the Company recognized compensation expenses as of December 31, 2019 and 2018 in the total amount of $5 and $0, respectively, included in general and administrative expenses. A summary of the Company’s option activity related to options to employees and directors, and related information is as followed:
|  | For the Year ended December 31, 2019 |
|  | Number of stock options |  |  | Weighted average exercise price |
Outstanding at beginning of period |  |  | 398,308 |  |  | $ | 11.50 |
Granted |  |  | 48,893 |  |  |  | 6.20 |
Cancelled |  |  | (28,690 | ) |  |  | - |
Forfeited |  |  | (47,151 | ) |  |  | - |
Outstanding at end of period |  |  | 371,360 |  |  | $ | 9.19 |
Vested at end of period |  |  | 270,827 |  |  | $ | 8.48 |
|  | For the Year ended December 31, 2018 |
|  | Number of stock options |  |  | Weighted average exercise price |
Outstanding at beginning of period |  |  | 414,965 |  |  | $ | 11.70 |
Granted |  |  | 10,000 |  |  |  | 9.00 |
Forfeited |  |  | (2,487 | ) |  |  | - |
Cancelled |  |  | (24,170 | ) |  |  | - |
Outstanding at end of period |  |  | 398,308 |  |  | $ | 11.50 |
Vested at end of period |  |  | 245,010 |  |  | $ | 8.45 |
The intrinsic value is calculated as the difference between the fair market value of the common stock and the exercise price, multiplied by the number of in-the-money stock options on those dates that would have been received by the stock option holders had all stock option holders exercised their stock options on those dates as of December 31, 2019 and December 31, 2018, respectively. As of December 31, 2019, and 2018, the aggregate intrinsic value of the outstanding options is $1,305 and $108 respectively, and the aggregate intrinsic value of the exercisable options is $1,115 and $108, respectively. As of December 31, 2019, there were approximately $1,157 of total unrecognized compensation costs, net of expected forfeitures, related to unvested share-based compensation awards granted under the Share Incentive Plan. The costs are expected to be recognized over a weighted average period of 1.4 years The stock options outstanding as of December 31, 2019 and December 31, 2018, summarized by exercise prices, are as follows:
Exercise price $ |  |  | Stock options outstanding as of December 31, 2019 |  |  | Stock options outstanding as of December 31, 2018 |  |  | Weighted average remaining contractual life – years as of December 31, 2019 |  |  | Weighted average remaining contractual life – years as of December 31, 2018 |  |  | Stock options exercisable as of December 31, 2019 |  |  | Stock options exercisable as of December 31, 2018 |
| 4.20 |  |  |  | 77,846 |  |  |  | 77,846 |  |  |  | 6.0 |  |  |  | 7.0 |  |  |  | 77,846 |  |  |  | 77,846 |
| 15.75 |  |  |  | 133,546 |  |  |  | 133,546 |  |  |  | 7.8 |  |  |  | 8.8 |  |  |  | 90,641 |  |  |  | 53,752 |
| 8.60 |  |  |  | 11,630 |  |  |  | - |  |  |  | 9.9 |  |  |  | - |  |  |  | 5,515 |  |  |  | - |
| 9.00 |  |  |  | 10,000 |  |  |  | 10,000 |  |  |  | 8.8 |  |  |  | 9.8 |  |  |  | 4,750 |  |  |  | - |
| 19.35 |  |  |  | 0 |  |  |  | 72,508 |  |  |  | 7.8 |  |  |  | 8.8 |  |  |  | - |  |  |  | 29,003 |
| 5.95 |  |  |  | 17,503 |  |  |  | - |  |  |  | 9.7 |  |  |  | - |  |  |  | - |  |  |  | - |
| 5.06 |  |  |  | 19,760 |  |  |  | - |  |  |  | 9.8 |  |  |  | - |  |  |  | - |  |  |  | - |
| 15.30 |  |  |  | 38,533 |  |  |  | 41,866 |  |  |  | 8.0 |  |  |  | 9.0 |  |  |  | 29,533 |  |  |  | 21,867 |
| (*) |  |  |  | 62,542 |  |  |  | 62,542 |  |  |  | 6.8 |  |  |  | 7.8 |  |  |  | 62,542 |  |  |  | 62,542 |
|  |  |  |  | 371,360 |  |  |  | 398,308 |  |  |  | 8.3 |  |  |  | 7.3 |  |  |  | 270,827 |  |  |  | 245,010 |
(*) Less than $0.01. Compensation expense recorded by the Company for its stock-based employee compensation awards in accordance with ASC 718-10 for the Years ended December 31, 2019 and 2018 was $1,099 and $1,399, respectively. The grant date fair values of stock options granted in the years ended December 31, 2019 and 2018 were estimated using the Black-Scholes valuation model with the following:
|  | Year ended December 31, 2019 |  | Year ended December 31, 2018
Expected volatility |  | 132.63%-144.4% |  | 99.40%
Risk-free interest |  | 1.49%-2.62% |  | 2.39%
Dividend yield |  | 0% |  | 0%
Expected life of up to (years) |  | 5.282 |  | 5.24
Shares issued to service provider On May 24, 2018 the Company issued an aggregate of 6,738 nonrefundable shares (100,000 nonrefundable shares before the Reverse Split) of common stock to CardioSert as part of certain patent acquisition. The Company recorded expenses of approximately $74 with respect to the issuance of these shares included in research and development expenses. Warrants The remaining outstanding warrants and terms as of December 31, 2019 and December 31, 2018 are as follows:
Issuance date |  | Outstanding as of December 31, 2018 |  |  | Outstanding as of December 31, 2019 |  |  | Exercise Price |  |  | Exercisable as of December 31, 2019 |  |  | Exercisable Through
Series A (2013) (*) |  |  | 183 |  |  |  | 183 |  |  | $ | 2,754.00 |  |  |  | 181 |  |  | April 9, 2023
Series A (2015) (*) |  |  | 683 |  |  |  | 683 |  |  | $ | 1,377.00 |  |  |  | 676 |  |  | April 30, 2020
Series B (2016) (a)(*) |  |  | 2,770 |  |  |  | 2,770 |  |  | $ | 40.50 |  |  |  | 2,741 |  |  | March 14, 2022
Warrant to underwriters 1.2019 |  |  | - |  |  |  | 22,767 |  |  | $ | 8.125 |  |  |  | 22,767 |  |  | July 14, 2022
Warrant to underwriters 1.2019 |  |  | - |  |  |  | 29,500 |  |  | $ | 12.50 |  |  |  | 29,500 |  |  | July 15, 2022
Warrant to underwriters 1.2019 |  |  | - |  |  |  | 12,500 |  |  | $ | 12.50 |  |  |  | 12,500 |  |  | January 15, 2020
Warrant to underwriters 12.2019 |  |  | - |  |  |  | 45,643 |  |  | $ | 13.125 |  |  |  | - |  |  | June 27, 2023
Warrant to underwriters 12.2019 |  |  | - |  |  |  | 47,619 |  |  | $ | 13.125 |  |  |  | - |  |  | June 30, 2023
Warrant to underwriters 12.2019 |  |  | - |  |  |  | 45,045 |  |  | $ | 13.875 |  |  |  | - |  |  | June 25, 2023
(*) Prior to January 1, 2019, warrants with non-standard anti-dilution provisions (referred to as down round protection) were classified as liabilities and re-measured each reporting period. On January 1, 2019, the Company adopted the provisions of ASU 2017-11, which indicates that a down round feature no longer precludes equity classification when assessing whether an investment is indexed to an entity’s own stock. The Company used a full retrospective approach to adoption and restated its financial statements as of the earliest period presented. The cumulative effect of adoption of ASU 2017-11 resulted in an adjustment to accumulated deficit as of January 1, 2018 of $20 with a corresponding adjustment to additional paid-in capital. In December 2019, 125,000 outstanding warrants at an exercise price per share of $10.00, were exercised on a “net exercise” or “cashless” basis into 61,677 shares of common stock, and 125,000 outstanding warrants at an exercise price per share of $10.00, were exercised on a “net exercise” or “cashless” basis into 50,143 shares of common stock. All of such warrants were issued in January 2019.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration